继发性未分化甲状腺癌1例及基因分析
A Case Report of Secondary Undifferentiated Thyroid Cancer and Genetic Analysis
DOI: 10.12677/acm.2024.14112990, PDF,   
作者: 刘 俊*, 杨见明#：安徽医科大学第二附属医院耳鼻咽喉头颈外科，安徽 合肥
关键词: 甲状腺乳头状癌；甲状腺未分化癌；共存；基因分析；Papillary Thyroid Carcinoma (PTC)； Anaplastic Thyroid Cancer (ATC)； Co-Existence； Genetic Analysis
摘要: 患者男性，84岁，以进行性吞咽困难起病，入院后术后病理提示甲状腺乳头状癌与未分化癌并存，在临床上较为罕见。
Abstract: A patient, 84 years old, with progressive dysphagia, was diagnosed as coexistence of papillary thyroid carcinoma and differentiated carcinoma through postoperative pathology, which is rare in clinical cases.
文章引用：刘俊, 杨见明. 继发性未分化甲状腺癌1例及基因分析[J]. 临床医学进展, 2024, 14(11): 1111-1120. https://doi.org/10.12677/acm.2024.14112990

参考文献

[1] National Health Commission of the People’s Republic of China Medical Administration and Hospital Administration. 甲状腺癌诊疗指南(2022年版) [J]. 中国实用外科杂志, 2022, 42(12): 1343-1357, 1363.
[2] Zheng, R.S., Sun, K.X., Zhang, S.W., Zeng, H.M., Zou, X.N., Chen, R., et al. (2019) Report of Cancer Epidemiology in China, 2015. Chinese Journal of Oncology, 41, 19-28.
[3] Xing, M. (2013) Molecular Pathogenesis and Mechanisms of Thyroid Cancer. Nature Reviews Cancer, 13, 184-199. [Google Scholar] [CrossRef] [PubMed]
[4] 赵晓文, 钱震, 朱萌, 等. 未分化甲状腺癌1例临床病理特征报道[J]. 诊断病理学杂志, 2022, 29(2): 177-178.
[5] Deeken-Draisey, A., Yang, G., Gao, J. and Alexiev, B.A. (2018) Anaplastic Thyroid Carcinoma: An Epidemiologic, Histologic, Immunohistochemical, and Molecular Single-Institution Study. Human Pathology, 82, 140-148. [Google Scholar] [CrossRef] [PubMed]
[6] Prior, I.A., Hood, F.E. and Hartley, J.L. (2020) The Frequency of Ras Mutations in Cancer. Cancer Research, 80, 2969-2974. [Google Scholar] [CrossRef] [PubMed]
[7] Lai, W., Liu, C., Lin, S., Chen, C. and Hang, J. (2020) Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors. Cancers, 12, Article 1973. [Google Scholar] [CrossRef] [PubMed]
[8] Pozdeyev, N., Rose, M.M., Bowles, D.W. and Schweppe, R.E. (2020) Molecular Therapeutics for Anaplastic Thyroid Cancer. Seminars in Cancer Biology, 61, 23-29. [Google Scholar] [CrossRef] [PubMed]
[9] Shi, X., Liu, R., Qu, S., Zhu, G., Bishop, J., Liu, X., et al. (2015) Association of TERT Promoter Mutation 1,295,228 C>T with BRAF V600E Mutation, Older Patient Age, and Distant Metastasis in Anaplastic Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 100, E632-E637. [Google Scholar] [CrossRef] [PubMed]
[10] Untch, B.R., Dos Anjos, V., Garcia-Rendueles, M.E.R., Knauf, J.A., Krishnamoorthy, G.P., Saqcena, M., et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 78, 4642-4657. [Google Scholar] [CrossRef] [PubMed]
[11] Garcia-Rendueles, M.E.R., Ricarte-Filho, J.C., Untch, B.R., Landa, I., Knauf, J.A., Voza, F., et al. (2015) NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discovery, 5, 1178-1193. [Google Scholar] [CrossRef] [PubMed]
[12] 王月华, 常苗苗, 王芳, 等. 原发性甲状腺非霍奇金淋巴瘤12例临床病理分析[J]. 临床与实验病理学杂志, 2019, 35(8): 957-958, 961.
[13] Wells, S.A., Asa, S.L., Dralle, H., Elisei, R., Evans, D.B., Gagel, R.F., et al. (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 25, 567-610. [Google Scholar] [CrossRef] [PubMed]
[14] 黄勇杰, 李炳权, 罗丽花, 等. 甲状腺髓样癌5例临床病理分析[J]. 安徽医药, 2022, 26(1): 161-164.
[15] Ciampi, R., Romei, C., Pieruzzi, L., Tacito, A., Molinaro, E., Agate, L., et al. (2016) Classical Point Mutations of RET, BRAF and RAS Oncogenes Are Not Shared in Papillary and Medullary Thyroid Cancer Occurring Simultaneously in the Same Gland. Journal of Endocrinological Investigation, 40, 55-62. [Google Scholar] [CrossRef] [PubMed]
[16] 张炳洲, 张波林, 张维, 等. 甲状腺血管肉瘤的诊断和治疗进展[J]. 中国现代手术学杂志, 2023, 27(3): 242-247.
[17] Bible, K.C., Kebebew, E., Brierley, J., Brito, J.P., Cabanillas, M.E., Clark, T.J., et al. (2021) 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 31, 337-386. [Google Scholar] [CrossRef] [PubMed]
[18] Tashima, L., Mitzner, R., Durvesh, S. and Goldenberg, D. (2011) Dyspnea as a Prognostic Factor in Anaplastic Thyroid Carcinoma. European Archives of Oto-Rhino-Laryngology, 269, 1251-1255. [Google Scholar] [CrossRef] [PubMed]
[19] Wagle, N., Grabiner, B.C., Van Allen, E.M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., et al. (2014) Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. New England Journal of Medicine, 371, 1426-1433. [Google Scholar] [CrossRef] [PubMed]
[20] Naing, A., Gainor, J.F., Gelderblom, H., Forde, P.M., Butler, M.O., Lin, C., et al. (2020) A First-in-Human Phase 1 Dose Escalation Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. Journal for ImmunoTherapy of Cancer, 8, e000530. [Google Scholar] [CrossRef] [PubMed]

为你推荐